About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
P
IMS 2022 on Updated Results of a Phase 1, First-in-Human Study of ABBV-383, a BCMA × CD3 Bispecific T-Cell Redirecting Antibody, in R/R MM
By
Peter Voorhees
2 Videos
October 5, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
19:14
Bristol Myers Squibb Hematology
Study Results of a Treatment Option for AML Patients
Feat.
J. Mccloskey,
T. Leblanc
Featured Video
15:50
Seagen
Efficacy and Safety Data of a First Line Treatment Option in Patient…
Feat.
A. Forman
Related Content
AUTOPLAY
ON
09:50
Nina Shah
Maximizing the Initial Gains in Myeloma Therapy: Consolidation and M…
15:31
Parameswaran Hari
Refractory and Relapsing Myeloma - When to Treat and Options Availab…
15:11
Ajay Nooka
Early Relapse: Choosing Among Different Second Line Regimens in Myel…
19:41
Peter Voorhees
Approach to the Patient with Refractory & Multiple Relapsed Mult…
18:44
City of Hope
The Promise of Immunotherapy and Newer Agents in Multiple Myeloma
Feat.
A. Krishnan
06:23
Parameswaran Hari
Treating Refractory & Relapsing Myeloma: Current Trends and Reco…
15:10
Krina Patel
Developing CAR T-cells in Multiple Myeloma
11:51
Memorial Sloan Kettering Cancer Center
Aiming for Minimal Residual Disease Negative Status in all Myeloma P…
Feat.
O. Landgren
05:24
Indy Hematology Review
Therapy for Relapsed Multiple Myeloma
Feat.
K. Anderson
12:32
Indy Hematology Review
What's New in Immunotherapy and Genomics in Multiple Myeloma?
Feat.
K. Anderson
17:47
Dana-Farber Cancer Institute
Relapse Refractory Myeloma and Novel Treatments
Feat.
N. S. Raje
15:02
Krina Patel
Clinical Trials in Myeloma in 2018
16:59
Nina Shah
The Future of CAR T Therapies in Myeloma in 2018
05:29
Nina Shah
Future Directions in Myeloma Post-ASCO Discussion
09:02
Maria-Victoria Mateos
FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma
08:15
2018 Pan Pacific Lymphoma Conference
Evolution of Myeloma Induction Regimens
Feat.
S. Holstein
11:57
2018 Pan Pacific Lymphoma Conference
Quadruplet Therapy in Myeloma, New Pembro Data and Relevance of Auto…
Feat.
S. Holstein
17:58
City of Hope
Should Everyone Receive Monoclonal Antibodies at First Myeloma Relap…
Feat.
J. Mikhael
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Myeloma State of the Art Update: Bone Disease, MRD Assessment, How t…
Feat.
S. Lonial
17:59
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Novel Agents, Antibodies, Targeted Therapies and Related Studies in …
Feat.
T. Martin
